Literature DB >> 10657977

Altered surface expression and increased turnover of the alpha6beta4 integrin in an undifferentiated carcinoma.

C M Witkowski1, G T Bowden, R B Nagle, A E Cress.   

Abstract

The integrin alpha6beta4, predominantly expressed on tissues of epithelial origin, is known to be variably expressed on carcinomas. The biochemical changes resulting in altered expression during tumor progression are unknown. We have analyzed the expression of alpha6beta4 in a multi-step mouse model of skin carcinogenesis representing normal keratinocyte, benign papilloma and malignant undifferentiated carcinoma. All cell lines expressed the alpha6 integrin exclusively as the alpha6beta4 integrin heterodimer. Analysis of this integrin by flow cytometry and immunoprecipitation of surface labeled proteins revealed that the undifferentiated carcinoma cells have an approximately 75% reduction in surface expression of the integrin as compared with the keratinocyte and papilloma cell lines. The alpha6beta4 integrin which remains expressed on the carcinoma cells is diffusely distributed in the membrane and has an approximately 2.5-fold increased biological turnover as compared with normal keratinocytes. The decreased biological half-life and the loss of polarized expression of alpha6beta4 on the carcinoma cells suggests an altered functional role for the alpha6beta4 integrin on carcinoma cells during tumor progression. These factors may contribute to the known supression of hemidesmosome structures and the increased migration phenotype associated with some epithelial carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10657977     DOI: 10.1093/carcin/21.2.325

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Identification of a novel structural variant of the alpha 6 integrin.

Authors:  T L Davis; I Rabinovitz; B W Futscher; M Schnölzer; F Burger; Y Liu; M Kulesz-Martin; A E Cress
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

2.  Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis.

Authors:  L Mariani; C Beaudry; W S McDonough; D B Hoelzinger; T Demuth; K R Ross; T Berens; S W Coons; G Watts; J M Trent; J S Wei; A Giese; M E Berens
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

3.  Laminin-binding integrin gene copy number alterations in distinct epithelial-type cancers.

Authors:  William L Harryman; Erika Pond; Parminder Singh; Andrew S Little; Jennifer M Eschbacher; Raymond B Nagle; Anne E Cress
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

4.  Integrin alpha6 cleavage: a novel modification to modulate cell migration.

Authors:  Sangita C Pawar; Manolis C Demetriou; Raymond B Nagle; G Tim Bowden; Anne E Cress
Journal:  Exp Cell Res       Date:  2007-01-17       Impact factor: 3.905

5.  Real-time imaging of integrin β4 dynamics using a reporter cell line generated by Crispr/Cas9 genome editing.

Authors:  Ameer L Elaimy; Mengdie Wang; Ankur Sheel; Caitlin W Brown; Melanie R Walker; John J Amante; Wen Xue; Amanda Chan; Christina E Baer; Hira Lal Goel; Arthur M Mercurio
Journal:  J Cell Sci       Date:  2019-07-31       Impact factor: 5.285

6.  Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis.

Authors:  Mary Ann Stepp; Sonali Pal-Ghosh; Gauri Tadvalkar; Lamise Rajjoub; Rosalyn A Jurjus; Michael Gerdes; Andrew Ryscavage; Christophe Cataisson; Anjali Shukla; Stuart H Yuspa
Journal:  Mol Carcinog       Date:  2010-04       Impact factor: 4.784

7.  Disassembly of α6β4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions.

Authors:  Tomasz Wenta; Anette Schmidt; Qin Zhang; Raman Devarajan; Prateek Singh; Xiayun Yang; Anne Ahtikoski; Markku Vaarala; Gong-Hong Wei; Aki Manninen
Journal:  Oncogene       Date:  2022-07-01       Impact factor: 8.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.